Clinical trials: Tirzepatide
Obesity / Overweight
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
This is an observational cohort study. The primary objective is to analyze the dynamic changes in gut microbiota and metabolic profiles in obese patients treated with Tirzepatide.
- Trial name
- NCT07847515
- Testing
- Tirzepatide
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Muscle Mass and Strength, Obesity & Overweight
Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment
This study aims to investigate the effect that a structured, progressive resistance exercise program may have on maintaining the muscle mass and physical function of overweight/ obese females whilst they experience a tirzepatide…
- Conditions
- Muscle Mass and Strength, Obesity & Overweight, Physical Function
- Trial name
- FLEX (NCT07457437)
- Testing
- Progressive Resistance Exercise Training Program, Habitual physical activity guidelines
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Obesity, Overweight and Obesity
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Obesity, affecting 40% of US adults and costing 173b annually, represents a significant health care burden (1). It is associated with increased risk for multiple chronic diseases including hypertension, type 2 diabetes (T2D)…
- Conditions
- Obesity, Overweight and Obesity, Overweight
- Trial name
- NCT05912621
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
Obese Diabetics, Obese Non Diabetic
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA…
- Trial name
- NCT07820111
- Testing
- Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
- Where
- Saudi Arabia
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Lactation, Weight Loss
Effects of GLP-1 RAs on Human Lactation Outcomes
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.
- Trial name
- NCT07720414
- Testing
- Injected GLP-1 Receptor Agonists and Dual Agonists
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Healthy
A Study of Tirzepatide (LY3298176) in Healthy Participants
This study has four parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC)…
- Trial name
- NCT03375463
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Diabetes
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
- Trial name
- NCT06657209
- Testing
- Insulin resistance testing, OGTT, Fat biopsy
- Where
- 2 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide.
- Trial name
- NCT06890611
- Testing
- Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction.
- Trial name
- DECODE (NCT07483801)
- Testing
- semaglutide, Tirzepatide
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Overweight, Obesity
A Study of LY3457263 in Obese Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants.
- Trial name
- NCT05582096
- Testing
- LY3457263, Tirzepatide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
GLP-1, Alcohol
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
- Trial name
- TAP (NCT07758231)
- Testing
- Acute Ethanol Dose
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Longevity, Preventive Medicine
Tirzepatide and Organ-specific Biological Aging
The purpose of this study is to evaluate blood-based measures of organ-specific biological age, with a particular focus on the brain, and to investigate their relationship with established clinical indicators of health and their…
- Conditions
- Longevity, Preventive Medicine, Biological Ageing
- Trial name
- NCT07906041
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Atria Research and Global Health Institute (ARGHI)
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Obesity & Overweight, Cardiometabolic Health Indicators
Tirzepatide Impact Assessment Study
This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body.
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders
- Trial name
- TIA (NCT07740291)
- Testing
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Obesity, Metabolic Disease
Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with double blind treatment to evaluate the effects of a drug called tirzepatide in combination with an innovative, culturally-appropriate…
- Trial name
- TRZ (NCT06009653)
- Testing
- Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Tirzepatide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine